Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi Loses Preliminary Injunction Bid Against Novo’s Levemir Promotional Materials

This article was originally published in The Pink Sheet Daily

Executive Summary

New Jersey federal court finds that Novo Nordisk’s claims regarding the insulin injection’s duration of effect and predictability are not literally false.

You may also be interested in...



Novo Nordisk Emphasizes Levemir “Predictability”

Planned second quarter launch would be nearly one year after FDA approval.

Tarceva Pancreatic Cancer Indication Turned Down In The EU

Roche will consider requesting a re-examination of the negative decision by the Committee for Medicinal Products for Human Use.

Teva To Investigate High-Dose Copaxone

A Phase III trial will compare 40 mg/day glatiramer to the 20 mg/day approved dose.

Topics

UsernamePublicRestriction

Register

PS064403

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel